|
IFN Gamma Prelicensing for Improved Mesenchymal Stromal Cell Function Post-Thaw
Application
Mesenchymal stromal cells (MSC) prelicensed with pro-inflammatory cytokines for improved survival and immunosuppressive properties following cryopreservation.
Key Benefits
Preserves the immunosuppressive function of MSCs following thawing.
Improves effectiveness of transplanted MSCs following cryopreservation.
Market Summary
Mesenchymal...
Published: 4/23/2024
Contributor(s): Jacques Galipeau, Raghavan Chinnadurai
|
|
rGIFT15: Recombinant Fusion Protein for the Treatment of Autoimmune Diseases
Application
Recombinant fusion protein comprising GM-CSF and interleukin-15 for treating autoimmune diseases.
Key Benefits
rGIFT15 lacks any post-translation modification such as glycosylation.
Market Summary
For those suffering from autoimmune diseases current therapies treat the symptoms, but do not provide a cure and currently available immunosuppressant...
Published: 7/28/2023
Contributor(s): Jacques Galipeau, Andrea Pennati
|
|
Membrane-anchored Fusokine as Vaccine Adjuvant to Prevent Viral Infection
Application
GIFT4 anchored to virus-like particles (VLPs) as a prophylactic vaccine adjuvant to prevent chronic viral infections including HIV, HBV, HPV and influenza.
Key Benefits
GIFT4-containing VLPs induce higher antibody response than non-adjuvanted VLPs.
Effectively induce strong mucosal immune response.
Market Summary
Currently, there...
Published: 4/23/2024
Contributor(s): Baozhong Wang, Richard Compans, Jacques Galipeau, Jiusheng Deng
|
|
FIST-15: Interleukin 15, Sushi Domain, and TGF-ß Receptor Fusion Protein Therapeutic
Application
A fusion protein that inhibits TGF-β signaling and enhances activation of CD8+ T cells and natural killer (NK) cells with applications in cancer immunotherapy, treatment of chronic viral infections, and cell therapy.
Key Benefits
Preserves the function of each component, blocking TGF-β signaling while enhancing Interleukin...
Published: 4/23/2024
Contributor(s): Spencer Ng, Jacques Galipeau
|
|
Recombinant Manufacturing Process for GIFT Fusion Cytokines
Application
A prokaryotic manufacturing process for efficient production of recombinant GIFT (GM-CSF & Interleukin Fusion Transgene) fusion cytokines as well as other recombinant therapeutics.
Key Benefits
Production via bacterial and yeast expression increases yield 1000 fold compared to mammalian systems while also decreasing cost and complexity.
GIFTs...
Published: 4/23/2024
Contributor(s): Jacques Galipeau, Andrea Pennati
|
|
GIFT4: GM-CSF and IL-4 Fusion Protein for Treating Cancer and Infectious Diseases
Application
A recombinant fusion cytokine that activates host immune responses for the treatment of cancer or infectious diseases and the development of adjuvant vaccines.
Key Benefits
Retains the immune stimulatory properties of both its parental molecules.
Displays novel functions such as direct activation of B cells leading to anti-cancer and...
Published: 4/23/2024
Contributor(s): Jacques Galipeau, Jiusheng Deng
|
|
GIFT7: A Novel Biologic to Treat Chronic Infections and Cancer
Application
A peptide therapeutic designed to stimulate an enhanced immune response for the treatment of infectious disease or certain cancers.
Key Benefits
Induces enhanced proliferation of T-cells compared to existing technologies to compensate for compromised immune conditions.
More efficacious in treating or preventing cancers when combined...
Published: 4/23/2024
Contributor(s): Jacques Galipeau, Hsiang-Chuan Hsieh
|